Cochlear Ltd
XMUN:OC5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cochlear Ltd
XMUN:OC5
|
AU |
|
M
|
Marriott Vacations Worldwide Corp
F:M8V
|
US |
|
ABC Arbitrage SA
OTC:ABCCF
|
FR |
|
O
|
OSI Systems Inc
XBER:OS2
|
US |
|
V
|
Volatus Aerospace Inc
XMUN:ABB
|
CA |
|
C
|
Cenovus Energy Inc
XBER:CXD
|
CA |
|
Greenvolt Energias Renovaveis SA
F:000
|
PT |
|
Spartan Delta Corp
F:4YJ0
|
CA |
Cochlear Ltd
Cochlear Ltd makes implantable hearing devices for people with severe hearing loss. Its main products are cochlear implants, which replace the function of damaged parts of the inner ear, along with the sound processors and other parts that work with them. The company also sells upgrades, replacement parts, and accessories that keep the systems working over time. Its customers are hospitals, ear, nose and throat surgeons, audiologists, hearing clinics, and ultimately patients who receive the implants. Cochlear earns money when it sells the implant systems, sound processors, and related consumables, and it also benefits from long-term follow-up needs such as replacements, accessories, and service support. That makes the business more than a one-time device sale; it has an ongoing relationship with each implanted patient. What sets Cochlear apart is that it sits at the high end of the hearing-care value chain, where the product is a medical implant rather than a hearing aid. The company depends on specialized research, surgery, and clinical support, so its business is closely tied to surgeons and medical centers rather than ordinary retail channels. This gives it a focused role in a niche but essential medical market.
Cochlear Ltd makes implantable hearing devices for people with severe hearing loss. Its main products are cochlear implants, which replace the function of damaged parts of the inner ear, along with the sound processors and other parts that work with them. The company also sells upgrades, replacement parts, and accessories that keep the systems working over time.
Its customers are hospitals, ear, nose and throat surgeons, audiologists, hearing clinics, and ultimately patients who receive the implants. Cochlear earns money when it sells the implant systems, sound processors, and related consumables, and it also benefits from long-term follow-up needs such as replacements, accessories, and service support. That makes the business more than a one-time device sale; it has an ongoing relationship with each implanted patient.
What sets Cochlear apart is that it sits at the high end of the hearing-care value chain, where the product is a medical implant rather than a hearing aid. The company depends on specialized research, surgery, and clinical support, so its business is closely tied to surgeons and medical centers rather than ordinary retail channels. This gives it a focused role in a niche but essential medical market.
Revenue Decline: Sales revenue declined by 2% in constant currency, mainly due to the timing and delays in the Nexa launch and related contracting.
Profit Impact: Underlying net profit was $195 million, with margins pressured by mix shift, higher launch costs, and FX headwinds.
Guidance Lowered: Full-year profit is now expected at the lower end of the original $4.35 to $4.60 range, excluding FX movements.
Nexa Launch: Nexa is now over 80% of developed market sales, but launch complexity and price negotiations caused short-term share loss and revenue delays.
Gross Margin Drop: Gross margin fell 2 points to 73%, mainly due to lower-margin emerging market mix, higher costs for Nexa at launch, and ramp-up of Chengdu.
FX Headwind: Recent Australian dollar strength could reduce profit by about $30 million in the second half if rates persist.
Service Growth Outlook: Service revenue grew 4% in developed markets and is expected to see a significant uplift in H2, aided by product retirements and upgrades.
Ongoing Restructuring: Strategic restructuring and R&D reorganization aim to support future growth, but no immediate cost savings are expected.
